Sarah Gitto, PhDUniversity of Pennsylania2022 Pape Family Scientific Scholar Award Transcriptomic and proteomic analysis of tumor-specific TILs to enhance immunotherapy in ovarian cancer Immunotherapies aim to enhance the immune system’s capability of eliminating disease within the body. Often, immunotherapy for cancer targets a type of immune cell called T cells to activate their ability to […]
Read More
Targeting STAT3 Signaling for Immune Checkpoint Blockade to Augment PARP Inhibitor Therapy in BRCA-Mutated Ovarian Cancer PARP inhibitors and immune checkpoint inhibitors are two promising new therapies for ovarian cancer patients who have mutations in the BRCA gene. BRCA-mutated ovarian cancer cells produce a protein called PD-L1 to avoid being recognized and killed by immune […]
Read More
Keith Knutson, PhDMayo Clinic Jacksonville2020 Cookie Laughlin Pilot Study Award Combination Th17-inducing vaccination and immune checkpoint blockade for ovarian cancer treatment Several types of immunotherapies that use the person’s own immune system to attack foreign “cancer” cells while leaving normal cells alone are being tested in ovarian cancer. Using immunotherapy to activate an immune pathway […]
Read More
Hua E Yu, PhDBeckman Research Institute of the City of Hope2020 Karla Mooers Pilot Study Award Targeting dePARylation activates anti-ovarian cancer immune responses The FDA has approved several types of PARP inhibitors for treating ovarian cancer. These drugs are especially effective at killing tumor cells that cannot repair damage that occurs to their DNA. One […]
Read More